Induction chemotherapy with 5-fluorouracil, cisplatin, and cetuximab in advanced head and neck squamous cell carcinoma

M Yamauchi, A Minesaki, T Ishida, Y Sato, S Okamura… - in vivo, 2023 - iv.iiarjournals.org
Background/Aim: Chemoradiotherapy (CRT) with high-dose cisplatin has become the
standard of care for larynx preservation in patients with locally advanced squamous cell …

[HTML][HTML] A multicenter phase ii trial of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for patients with local advanced …

S Zenda, Y Ota, N Kiyota, S Okano, M Fujii… - Frontiers in …, 2019 - frontiersin.org
Background: Induction chemotherapy (IC) is a treatment option for locally advanced
squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with …

TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck

P Strojan, CG Kuhar, B Žumer, M Kadivec… - Head & …, 2014 - Wiley Online Library
Background The purpose of this study was to assess the efficacy and toxicity of docetaxel,
cisplatin/5‐fluorouracil (TPF) induction chemotherapy and concomitant …

Induction chemotherapy with cisplatin, 5-fluorouracil, and cetuximab followed by radiotherapy and cetuximad in head and neck cancers: Preliminary results of a …

RM D'Angelillo, L Trodella, F Cellini, M Fiore… - Journal of Clinical …, 2011 - ascopubs.org
e16030 Background: To determine feasibility and efficacy of induction chemotherapy (ICT)
with cisplatin, 5-fluorouracil and cetuximab, followed by concurrent cetuximab and …

Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in …

R Hitt, R Mesía, A Lozano, LI Docampo, JJ Grau… - Oral Oncology, 2022 - Elsevier
Objectives Concurrent chemoradiotherapy is the standard treatment for patients with
unresectable, locally advanced squamous cell carcinoma of the head and neck (LA …

Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell …

L de Souza Viana, FC de Aguiar Silva… - Head & …, 2016 - Wiley Online Library
Background The purpose of this phase II trial was to evaluate the tolerability, safety, and
efficacy of a non–5‐fluorouracil (5‐FU)‐based induction chemotherapy followed by …

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell …

T Enokida, T Ogawa, A Homma, K Okami… - Cancer …, 2020 - Wiley Online Library
Background Induction chemotherapy (IC) in locally advanced squamous cell carcinoma of
the head and neck (LA‐SCCHN) often compromises compliance with subsequent …

Predictive factors for completion of TPF induction chemotherapy in patients with locally advanced head and neck cancer

K Nakano, A Seto, T Sasaki, W Shimbashi… - Anticancer …, 2019 - ar.iiarjournals.org
Background: Induction therapy with docetaxel, cisplatin and fluorouracil (TPF) is a treatment
option for locally advanced head and neck cancer (LAHNC), but it is not known which …

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck

RI Haddad, RB Tishler, C Norris, L Goguen… - Journal of clinical …, 2009 - ascopubs.org
Purpose Phase I study to determine the maximum tolerated dose (MTD) of fluorouracil (FU)
in the docetaxel/cisplatin/FU (TPF) regimen when combined with cetuximab (C) for induction …

Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer

S Okano, T Enokida, T Onoe, Y Ota, A Motegi… - International Journal of …, 2019 - Springer
Background In treatment of locally advanced squamous cell carcinoma of the head and neck
(SCCHN), the use of docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by high-dose …